Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Arcutis schedules a webcast fireside chat at Morgan Stanley’s 2026 Global Healthcare Conference, with a replay available online for 180 days.
Rhea-AI Summary
Arcutis Biotherapeutics (ARQT) will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14-16, 2026.
Management will participate in a fireside chat on Wednesday, September 16, 2026, at 1:50 p.m. ET. A live webcast and replay will be available in the “Events” section of the company’s website, with replay access for 180 days after the conference.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 07 | Inducement grants | Neutral | +2.5% | Grants of restricted stock units and options to newly hired employees |
| Aug 05 | Second-quarter earnings | Positive | -2.5% | Quarterly revenue growth and raised full-year net product sales guidance |
| Jul 16 | Board appointment | Neutral | -0.1% | Christopher Peetz joined the board to support franchise and pipeline expansion |
| Jul 15 | Earnings scheduling | Neutral | -0.1% | Company scheduled second-quarter results and an investor conference call |
| Jul 08 | FDA application acceptance | Positive | +3.0% | FDA accepted the supplemental application and set a PDUFA target date |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive announcements produced mixed reactions, including a -2.47% move after earnings and a +3% move after FDA acceptance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Morgan Stanley 24th Annual Global Healthcare Conference, taking place September 14-16, 2026, in New York.
Details for the Company’s participation are as follows:
Fireside Chat: Wednesday, September 16, 2026, at 1:50 p.m. ET
The webcast for this conference may be accessed via the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis’ unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, head of Investor Relations
ir@arcutis.com
